Welcome to our dedicated page for Biofrontera SEC filings (Ticker: BFRIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biofrontera Inc. warrants (BFRIW) SEC filings page provides direct access to the regulatory documents that describe both the warrant security and the broader Biofrontera Inc. business. Company filings identify BFRIW as warrants to purchase common stock of Biofrontera Inc., whose common shares trade on The Nasdaq Capital Market under the symbol BFRI. These documents outline listing details, capital structure changes, and transactions relevant to holders of the warrants and the underlying equity.
Through registration statements such as the S‑1/A, investors can review descriptions of Biofrontera’s operations, including its focus on photodynamic therapy in dermatology, its principal licensed product Ameluz® used with RhodoLED® lamps for actinic keratoses, and its status as an emerging growth and smaller reporting company. Forms 8‑K capture material events such as financings with Series C and Series D Convertible Preferred Stock, the strategic transaction with Biofrontera AG to acquire all U.S. rights to Ameluz and RhodoLED, and stockholder approvals for reverse stock split authority and preferred stock conversions.
Proxy materials (such as the DEF 14A for a special meeting) detail stockholder proposals related to reverse splits, increases in authorized common stock, and approvals required under Nasdaq rules for preferred stock conversions. Other 8‑K filings report on matters such as financial results, appointment of key officers, and submission of matters to a vote of security holders.
On this page, users can follow Biofrontera’s 10‑K and 10‑Q reports (when filed), 8‑Ks, registration statements, and proxy statements as they become available from EDGAR. Stock Titan’s platform adds AI-powered summaries to help explain the main points of lengthy filings, highlight changes in capital structure that may affect BFRIW, and clarify how clinical, regulatory, and transactional disclosures relate to Biofrontera’s dermatology-focused business.
Amendment No. 3 to Schedule 13D shows that Biofrontera AG ("BFAG") and related German investment vehicles—Deutsche Balaton AG, VV Beteiligungen AG, Delphi Unternehmensberatung AG—and six individuals now collectively control 458,884 Biofrontera Inc. shares, or 4.86 % of the 9,446,197 shares outstanding. BFAG itself holds 400,000 shares (4.23 %). Dilution from successive equity issuances and a 1-for-20 reverse split pushed each filer below the 5 % reporting threshold.
Key new element: on 30 Jun 2025 BFAG transferred all U.S. rights to Ameluz and RhodoLED back to the issuer. In return BFAG received (i) a 12 – 15 % royalty on future U.S. Ameluz sales (rate rises above US$65 m revenue) and (ii) 3,019 shares of Series D Convertible Preferred Stock. Each preferred share converts into common at US$0.6249, equating to 4,831,172 common shares. Conversion and associated voting rights are blocked until shareholder approval.
If conversion is approved, BFAG’s stake would jump to roughly 51 % of current shares outstanding, restoring majority control and giving BFAG the right to appoint up to two directors for three years. Deutsche Balaton indicates it may buy or sell additional shares depending on market conditions; the other reporting persons currently have no direct purchase plans. No criminal or civil proceedings involve the filers, though DB has ongoing German litigation against BFAG concerning the 2021 IPO.